Smart-ring maker Oura is buying its way into the doctor's office. The company said on Tuesday it has agreed to acquire Counsel Health, an AI-native primary care startup, for $625 million in cash — a deal that would pair Oura's continuous biometric data with an AI chatbot and on-demand physicians inside a single app.
Counsel Health combines a chat-based medical interface with access to licensed, board-certified physicians. Members can ask the AI about everyday health questions and, when needed, speak to a doctor who can diagnose and prescribe — turning the ring's stream of sleep, heart-rate and activity data into something a clinician can actually act on.
From ring data to a real doctor
The two companies are not strangers. Counsel's AI chatbot was already integrated into the Oura app earlier this year, letting members get AI-generated health insights based on their wearable data. The acquisition folds that relationship into Oura itself: Counsel's chief executive, Muthu Alagappan, will join Oura as chief clinical AI officer, and the startup's roughly 70 employees will move across with him.
Oura chief executive Tom Hale told Bloomberg the plan is to connect wearables, clinical AI and access to doctors, using biometric insights to answer questions and monitor ongoing conditions. It is the clearest sign yet that Oura sees its future less as a gadget company and more as a health platform.
A big bet after the shelved IPO
The deal comes only weeks after Oura postponed its planned initial public offering indefinitely, citing uncertainty in the IPO market. The listing had been expected to value the company at up to $2.2 billion; Oura was valued at about $11 billion in a late-stage funding round last year. A $625 million all-cash acquisition is a substantial cheque for a private company — roughly a third of its annual revenue — and a signal that Oura would rather spend than wait for public markets to cooperate.
The numbers behind the confidence are striking. Oura reported preliminary revenue of $533 million for the quarter ended September 30, up 153 percent year over year, and about $1.75 billion for fiscal 2026, up 92 percent. The company says it now has more than six million members. The figures are preliminary and unaudited.
What happens next
The transaction is expected to close before the end of the calendar year, subject to customary closing conditions. Counsel raised a $25 million Series A round a year ago, led by Andreessen Horowitz and GV, so the $625 million price tag represents a sharp mark-up for a startup barely out of its early funding rounds.
There is one line Oura is careful not to cross. The company stresses that its ring is not a medical device and is not intended to diagnose, treat or track illness. Buying a primary-care company moves Oura closer to clinical care than any wearable maker has gone before — without, for now, claiming the ring itself is medicine.



